The American Academy of Ophthalmology has asked CMS and HHS to prohibit Medicare Advantage and exchange plans from suggesting biosimilar alternatives to Avastin, according to a press release.
Avastin (bevacizumab, Genentech) is an anti-VEGF therapy used off label to treat age-related macular degeneration and other vision-threatening diseases, “supported by years of published research validating its effectiveness and safety for use in the eye,” the release said.
A production process overhaul has disrupted the Avastin supply chain, and in the vacuum, some insurance companies,